• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Chinook Therapeutics Inc.

    6/7/22 4:45:42 PM ET
    $KDNY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $KDNY alert in real time by email
    SC 13G 1 c060722a.htm SCHEDULE 13G
    240.13d-102 Schedule 13G - Information to be included in statements filed
    pursuant to 240.13d-1(b), (c), and (d) and amendments thereto
    filed pursuant to 240.13d-2.
    Securities and Exchange Commission, Washington, D.C. 20549
    Schedule 13G
    Under the Securities Exchange Act of 1934
    (Amendment No._)*
    (Name of Issuer)
    Chinook Therapeutics, Inc.
    (Title of Class of Securities)
    Common Stock, Par Value $0.0001 Per Share

    (CUSIP Number)

    16961L106

    (Date of Event Which Requires Filing of this Statement)
    May 27, 2022
    Check the appropriate box to designate the rule pursuant to which this
    Schedule is filed:
    [  ] Rule 13d-1(b)
    [ x ] Rule 13d-1(c)
    [  ] Rule 13d-1(d)
    *The remainder of this cover page shall be filled out for a reporting person's
    initial filing on this form with respect to the subject class of securities, and
    for any subsequent amendment containing information which would alter the
    disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be
    deemed to be “filed” for the purpose of Section 18 of the Securities Exchange
    Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the
    Act but shall be subject to all other provisions of the Act (however, see
    the Notes).




    CUSIP No. 16961L106
    (1) Names of reporting persons    Point72 Asset Management, L.P.
     
    (2) Check the appropriate box if a member of a group
    (a)
    (see instructions)
    (b)X
    (3) SEC use only
     
    (4) Citizenship or place of organization Delaware
     
    Number of shares beneficially owned by each reporting person with:
     
    (5) Sole voting power                  0
     
    (6) Shared voting power              3,047,732 (see Item 4)
     
    (7) Sole dispositive power           0
     
    (8) Shared dispositive power       3,047,732 (see Item 4)
     
    (9) Aggregate amount beneficially owned by each reporting person
    3,047,732 (see Item 4)
     
    (10) Check if the aggregate amount in Row (9) excludes certain shares
    (see instructions)
     
    (11) Percent of class represented by amount in Row (9) 5.0% (a) (see Item 4)
     
    (12) Type of reporting person (see instructions) PN
     


    CUSIP No. 16961L106
    (1) Names of reporting persons    Point72 Capital Advisors, Inc.
     
    (2) Check the appropriate box if a member of a group
    (a)
    (see instructions)
    (b)X
    (3) SEC use only
     
    (4) Citizenship or place of organization Delaware
     
    Number of shares beneficially owned by each reporting person with:
     
    (5) Sole voting power                  0
     
    (6) Shared voting power              3,047,732 (see Item 4)
     
    (7) Sole dispositive power           0
     
    (8) Shared dispositive power       3,047,732 (see Item 4)
     
    (9) Aggregate amount beneficially owned by each reporting person
    3,047,732 (see Item 4)
     
    (10) Check if the aggregate amount in Row (9) excludes certain shares
    (see instructions)
     
    (11) Percent of class represented by amount in Row (9) 5.0% (a)  (see Item 4)
     
    (12) Type of reporting person (see instructions) CO
     


    CUSIP No. 16961L106
    (1) Names of reporting persons    Cubist Systematic Strategies, LLC
     
    (2) Check the appropriate box if a member of a group
    (a)
    (see instructions)
    (b)X
    (3) SEC use only
     
    (4) Citizenship or place of organization Delaware
     
    Number of shares beneficially owned by each reporting person with:
     
    (5) Sole voting power                  0
     
    (6) Shared voting power              69,748 (see Item 4)
     
    (7) Sole dispositive power           0
     
    (8) Shared dispositive power       69,748 (see Item 4)
     
    (9) Aggregate amount beneficially owned by each reporting person
    69,748 (see Item 4)
     
    (10) Check if the aggregate amount in Row (9) excludes certain shares
    (see instructions)
     
    (11) Percent of class represented by amount in Row (9) 0.1% (a) (see Item 4)
     
    (12) Type of reporting person (see instructions) OO
     


    CUSIP No. 16961L106
    (1) Names of reporting persons    Steven A. Cohen
     
    (2) Check the appropriate box if a member of a group
    (a)
    (see instructions)
    (b)X
    (3) SEC use only
     
    (4) Citizenship or place of organization United States
     
    Number of shares beneficially owned by each reporting person with:
     
    (5) Sole voting power                  0
     
    (6) Shared voting power              3,117,480 (see Item 4)
     
    (7) Sole dispositive power           0
     
    (8) Shared dispositive power       3,117,480 (see Item 4)
     
    (9) Aggregate amount beneficially owned by each reporting person
    3,117,480 (see Item 4)
     
    (10) Check if the aggregate amount in Row (9) excludes certain shares
    (see instructions)
     
    (11) Percent of class represented by amount in Row (9) 5.1% (a) (see Item 4)
     
    (12) Type of reporting person (see instructions) IN
     



    Item 1(a) Name of issuer:
    Chinook Therapeutics, Inc.
    Item 1(b) Address of issuer's principal executive offices:
    400 Fairview Avenue North, Suite 900, Seattle, Washington 98109
    2(a) Name of person filing:
    This statement is filed by: (i) Point72 Asset Management, L.P. (“Point72 Asset
    Management”) with respect to shares of common stock, par value $0.0001 per
    share (“Shares”), of the Issuer held by certain investment funds it manages;
    (ii) Point72 Capital Advisors, Inc. (“Point72 Capital Advisors Inc.”) with
    respect to Shares held by certain investment funds managed by Point72 Asset
    Management; (iii) Cubist Systematic Strategies, LLC (“Cubist Systematic
    Strategies”) with respect to Shares held by certain investment funds it
    manages; and (iv) Steven A. Cohen (“Mr. Cohen”) with respect to Shares
    beneficially owned by Point72 Asset Management, Point72 Capital Advisors Inc.,
    and Cubist Systematic Strategies.

    Point72 Asset Management, Point72 Capital Advisors Inc., Cubist Systematic
    Strategies, and Mr. Cohen have entered into a Joint Filing Agreement, a copy of
    which is filed with this Schedule 13G as Exhibit 99.1, pursuant to which they
    have agreed to file this Schedule 13G jointly in accordance with the
    provisions of Rule 13d-1(k) of the Act.
    2(b) Address or principal business office or, if none, residence:
    The address of the principal business office of (i) Point72 Asset Management,
    Point72 Capital Advisors Inc., and Mr. Cohen is 72 Cummings Point Road,
    Stamford, CT 06902; and (ii) Cubist Systematic Strategies is 55 Hudson Yards,
    New York, NY 10001.
    2(c) Citizenship:
    Point72 Asset Management is a Delaware limited partnership. Point72 Capital
    Advisors Inc. is a Delaware corporation. Cubist Systematic Strategies is a
    Delaware limited liability company. Mr. Cohen is a United States citizen.
    2(d) Title of class of securities:
    Common Stock, Par Value $0.0001 Per Share
    2(e) CUSIP Number:
    16961L106

    Item 3.

    Not applicable

    Item 4. Ownership

    As of the close of business on June 6, 2022:

    1. Point72 Asset Management, L.P.
    (a) Amount beneficially owned: 3,047,732
    (b) Percent of class: 5.0% (a)
    (c) Number of shares as to which the person has:
    (i) Sole power to vote or to direct the vote: 0
    (ii) Shared power to vote or to direct the vote: 3,047,732 
    (iii) Sole power to dispose or to direct the disposition of: 0
    (iv) Shared power to dispose or to direct the disposition of: 3,047,732

    2. Point72 Capital Advisors, Inc.
    (a) Amount beneficially owned: 3,047,732
    (b) Percent of class: 5.0% (a) 
    (c) Number of shares as to which the person has:
    (i) Sole power to vote or to direct the vote: 0
    (ii) Shared power to vote or to direct the vote: 3,047,732 
    (iii) Sole power to dispose or to direct the disposition of: 0
    (iv) Shared power to dispose or to direct the disposition of: 3,047,732

    3. Cubist Systematic Strategies, LLC
    (a) Amount beneficially owned: 69,748
    (b) Percent of class: 0.1% (a)
    (c) Number of shares as to which the person has:
    (i) Sole power to vote or to direct the vote: 0
    (ii) Shared power to vote or to direct the vote: 69,748 
    (iii) Sole power to dispose or to direct the disposition of: 0
    (iv) Shared power to dispose or to direct the disposition of: 69,748

    4. Steven A. Cohen
    (a) Amount beneficially owned: 3,117,480
    (b) Percent of class: 5.1% (a) 
    (c) Number of shares as to which the person has:
    (i) Sole power to vote or to direct the vote: 0
    (ii) Shared power to vote or to direct the vote: 3,117,480 
    (iii) Sole power to dispose or to direct the disposition of: 0
    (iv) Shared power to dispose or to direct the disposition of: 3,117,480

    (a)
    This calculation is based on 61,545,185 shares of Common Stock outstanding
    as of May 27, 2022, as reported in the Issuer’s final prospectus supplement dated
    May 24, 2022, filed on May 25, 2022 with the Securities and Exchange Commission. 

    Point72 Asset Management, Point72 Capital Advisors Inc., Cubist Systematic
    Strategies, and Mr. Cohen own directly no Shares. Pursuant to an investment
    management agreement, Point72 Asset Management maintains investment and
    voting power with respect to the securities held by certain investment funds it
    manages. Point72 Capital Advisors Inc. is the general partner of Point72 Asset
    Management. Pursuant to an investment management agreement, Cubist Systematic
    Strategies maintains investment and voting power with respect to the securities
    held by certain investment funds it manages. Mr. Cohen controls each of Point72
    Asset Management, Point72 Capital Advisors Inc., and Cubist Systematic
    Strategies. By reason of the provisions of Rule 13d-3 of the Securities Exchange
    Act of 1934, as amended, each of (i) Point72 Asset Management, Point72
    Capital Advisors Inc., and Mr. Cohen may be deemed to beneficially own
    3,047,732 Shares (constituting approximately 5.0% of the Shares outstanding)
    and (ii) Cubist Systematic Strategies and Mr. Cohen may be deemed to beneficially
    own 69,748 Shares (constituting approximately 0.1% of the Shares outstanding).
    Each of Point72 Asset Management, Point72 Capital Advisors Inc., Cubist
    Systematic Strategies, and Mr. Cohen disclaims beneficial ownership of any
    of the securities covered by this statement.

    Item 5. Ownership of 5 Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof
    the reporting person has ceased to be the beneficial owner of more than
    5 percent of the class of securities, check the following [].

    Item 6.  Ownership of More than 5 Percent on Behalf of Another Person.

    Not applicable

    Item 7.  Identification and Classification of the Subsidiary Which Acquired
    the Security Being Reporting on by the Parent Holding Company or Control
    Person.
    Not applicable
    Item 8. Identification and Classification of Members of the Group

    Not applicable

    Item 9.  Notice of Dissolution of Group.

    Not applicable

    Item 10. Certifications

    By signing below I certify that, to the best of my knowledge and belief,
    the securities referred to above were not acquired and are not held for the purpose
    of or with the effect of changing or influencing the control of the issuer of
    the securities and were not acquired and are not held in connection with or
    as a participant in any transaction having that purpose or effect, other than activities
    solely in connection with a nomination under§ 240.14a-11.

    Signature.  After reasonable inquiry and to the best of my knowledge and belief,
    I certify that the information set forth in this statement is true, complete
    and correct.
    Dated: June 7, 2022
    POINT72 ASSET MANAGEMENT, L.P.
    By: /s/ Jason M. Colombo
    Name: Jason M. Colombo
    Title: Authorized Person

    POINT72 CAPITAL ADVISORS, INC.
    By: /s/ Jason M. Colombo
    Name: Jason M. Colombo
    Title: Authorized Person

    CUBIST SYSTEMATIC STRATEGIES, LLC
    By: /s/ Jason M. Colombo
    Name: Jason M. Colombo
    Title: Authorized Person

    STEVEN A. COHEN
    By: /s/ Jason M. Colombo
    Name: Jason M. Colombo
    Title: Authorized Person
    Get the next $KDNY alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $KDNY

    DatePrice TargetRatingAnalyst
    8/8/2023$42.00Outperform → Neutral
    Wedbush
    3/6/2023$41.00Overweight
    Piper Sandler
    3/1/2023$43.00Buy
    Guggenheim
    12/5/2022$30.00Overweight
    Wells Fargo
    6/28/2022$30.00Buy
    Stifel
    More analyst ratings

    $KDNY
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Chinook Therapeutics Announces First Patient Enrolled in Pivotal Phase 3 BEYOND Study of Zigakibart (BION-1301) for Patients with IgA Nephropathy

      SEATTLE, July 28, 2023 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ:KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that the first patient with IgA nephropathy (IgAN) has been enrolled in the BEYOND study, a pivotal phase 3 clinical trial evaluating the safety and efficacy of zigakibart (BION-1301), a potentially disease-modifying anti-APRIL monoclonal antibody. "Initiation of the phase 3 BEYOND study is an important step towards our goal of providing an innovative treatment option for patients with IgAN, a disease with high unmet need and limited treatment options," said E

      7/28/23 8:00:00 AM ET
      $KDNY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lifshitz Law PLLC Announces Investigations of BG, KDNY, QUOT, and DICE

      NEW YORK, June 24, 2023 (GLOBE NEWSWIRE) -- Bunge Limited (NYSE:BG) Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the merger of BG and Viterra Limited. Under the terms of the agreement, Viterra Limited shareholders will receive approximately 65.6 million shares of BG common stock and $2.0 billion in cash. In addition, BG will assume $9.8 billion of Viterra Limited debt and BG plans to repurchase $2.0 billion of BG common stock. If you are a BG investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-m

      6/24/23 8:11:00 PM ET
      $BG
      $DICE
      $KDNY
      $QUOT
      Packaged Foods
      Consumer Staples
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chinook Therapeutics Presents Data from CHK-336 Phase 1 Trial in Healthy Volunteers and New Insights into the Role of Failed Repair in Chronic Kidney Disease at the 60th European Renal Association (ERA) Congress

      CHK-336 was generally well tolerated in healthy volunteers (HV) who received single doses up to 500 mg and multiple doses up to 60 mg for 14 daysPharmacokinetics (PK) was well characterized with dose-proportional exposures and a half-life that supports once-daily dosingSuccessful implementation of a novel 13C2-glycolate tracer established proof-of-mechanism of CHK-336 to block hepatic oxalate production in HVsOne serious adverse event (SAE) of anaphylaxis occurred in a multiple ascending dose HV who received one 125 mg dose CHK-336, resulting in voluntary study pauseAdditional research presented on the impact of maladaptive tubular epithelial cells on progression of chronic kidney disease S

      6/17/23 7:15:00 AM ET
      $KDNY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KDNY
    SEC Filings

    See more
    • SEC Form 15-12G filed by Chinook Therapeutics Inc.

      15-12G - CHINOOK THERAPEUTICS, INC. (0001435049) (Filer)

      8/21/23 1:21:49 PM ET
      $KDNY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Chinook Therapeutics Inc.

      EFFECT - CHINOOK THERAPEUTICS, INC. (0001435049) (Filer)

      8/17/23 12:15:05 AM ET
      $KDNY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 POS filed by Chinook Therapeutics Inc.

      S-8 POS - CHINOOK THERAPEUTICS, INC. (0001435049) (Filer)

      8/11/23 5:02:27 PM ET
      $KDNY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KDNY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Chinook Therapeutics downgraded by Wedbush with a new price target

      Wedbush downgraded Chinook Therapeutics from Outperform to Neutral and set a new price target of $42.00

      8/8/23 7:33:22 AM ET
      $KDNY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Piper Sandler initiated coverage on Chinook Therapeutics with a new price target

      Piper Sandler initiated coverage of Chinook Therapeutics with a rating of Overweight and set a new price target of $41.00

      3/6/23 9:13:06 AM ET
      $KDNY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Guggenheim initiated coverage on Chinook Therapeutics with a new price target

      Guggenheim initiated coverage of Chinook Therapeutics with a rating of Buy and set a new price target of $43.00

      3/1/23 6:16:33 AM ET
      $KDNY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KDNY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Chinook Therapeutics Inc. (Amendment)

      SC 13D/A - CHINOOK THERAPEUTICS, INC. (0001435049) (Subject)

      11/22/23 4:15:46 PM ET
      $KDNY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by Chinook Therapeutics Inc.

      SC 13D - CHINOOK THERAPEUTICS, INC. (0001435049) (Subject)

      8/11/23 5:17:17 PM ET
      $KDNY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Chinook Therapeutics Inc. (Amendment)

      SC 13G/A - CHINOOK THERAPEUTICS, INC. (0001435049) (Subject)

      8/1/23 8:56:01 AM ET
      $KDNY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KDNY
    Leadership Updates

    Live Leadership Updates

    See more
    • Chinook Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Updates

      SEATTLE, May 09, 2023 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ:KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today reported financial results for the first quarter ended March 31, 2023 and provided corporate updates. "During the first quarter of 2023, we continued to advance our pipeline of clinical and preclinical programs for rare, severe chronic kidney diseases. We recently completed full enrollment of the phase 3 ALIGN clinical trial, are on track to initiate the phase 3 BION-1301 IgAN clinical trial mid-year and expect to report topline ALIGN results in the fourth quarter of thi

      5/9/23 4:00:00 PM ET
      $KDNY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chinook Therapeutics Announces the Appointment of Robert W. Azelby to its Board of Directors

      SEATTLE, April 13, 2023 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ:KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced the appointment of Robert W. Azelby to its Board of Directors. Mr. Azelby brings more than 20 years of executive leadership and commercial experience in the biopharmaceutical industry to Chinook. "We are thrilled to welcome Bob to Chinook's board of directors as we advance our pipeline through key milestones in 2023 and beyond," said Eric Dobmeier, president and chief executive officer of Chinook Therapeutics. "Bob brings significant industry experience in bu

      4/13/23 8:00:00 AM ET
      $KDNY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chinook Therapeutics Announces the Appointment of Andrew Oxtoby as Chief Commercial Officer

      SEATTLE, Feb. 15, 2023 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ:KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced the appointment of Andrew Oxtoby as chief commercial officer. "We are pleased to welcome Andrew to Chinook as we prepare for a year of important milestones for our atrasentan and BION-1301 programs," said Eric Dobmeier, president and chief executive officer of Chinook Therapeutics. "Andrew is an accomplished industry leader with more than 20 years of global biopharmaceutical experience and a proven track record of building commercial strategies and executing n

      2/15/23 8:00:00 AM ET
      $KDNY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KDNY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Thomas Dolca returned 13,300 shares to the company, closing all direct ownership in the company

      4 - CHINOOK THERAPEUTICS, INC. (0001435049) (Issuer)

      8/11/23 4:11:53 PM ET
      $KDNY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Oxtoby Andrew

      4 - CHINOOK THERAPEUTICS, INC. (0001435049) (Issuer)

      8/11/23 4:11:17 PM ET
      $KDNY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Krishnan Mahesh returned 1,275 shares to the company, closing all direct ownership in the company

      4 - CHINOOK THERAPEUTICS, INC. (0001435049) (Issuer)

      8/11/23 4:10:52 PM ET
      $KDNY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KDNY
    Financials

    Live finance-specific insights

    See more
    • Chinook Therapeutics to Present Updated Data from Zigakibart (BION-1301) Phase 1/2 Trial in Patients with IgA Nephropathy (IgAN) at the 60th European Renal Association (ERA) Congress

      Zigakibart treatment continues to demonstrate rapid and sustained reductions in mechanistic biomarkers, including IgA and Gd-IgA1 levels, which correspond to clinically meaningful proteinuria reductions in patients with IgAN across Cohorts 1 and 2Zigakibart is well-tolerated, with no ADAs observed or treatment discontinuations due to adverse events (AEs) in patients with IgAN across Cohorts 1 and 2 In all patients combined from both Cohorts 1 and 2, zigakibart demonstrated mean proteinuria reductions of 20% at 12 weeks of treatment, 39% at 24 weeks of treatment and 67% at 52 weeks of treatmentExtended treatment with zigakibart resulted in sustained clinical benefit, with 67% mean proteinuria

      6/12/23 4:00:00 PM ET
      $KDNY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chinook Therapeutics Announces Upcoming Presentations and Investor Conference Call at the 60th European Renal Association (ERA) Congress

      Updated interim data to be presented from Cohort 1 and 2 of the ongoing phase 1/2 study of BION-1301 in patients with IgANInitial data to be presented from the phase 1 study of CHK-336 in healthy volunteersAdditional presentations on the design of the phase 2 ASSIST study for atrasentan in patients with IgAN on background RASi and SGLT2i and the phase 3 BEYOND study of BION-1301 in patients with IgAN, as well as research on the impact of maladaptive tubular epithelial cells on disease progression in chronic kidney diseasesChinook to host investor conference call and webcast on June 16, 2023 at 8:15 am EDT to review and discuss the presentations and provide corporate updates SEATTLE, May 05

      5/5/23 4:00:00 PM ET
      $KDNY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chinook Therapeutics Presents Updated Data from BION-1301 Phase 1/2 Trial in Patients with IgA Nephropathy (IgAN) and CHK-336 Preclinical Efficacy Data at the American Society of Nephrology (ASN) Kidney Week 2022

      The initial response to de novo subcutaneous (SC) BION-1301 treatment in Cohort 2 is highly consistent with Cohort 1 across both mechanistic biomarkers and proteinuria reductionsBION-1301 is well-tolerated, with no serious adverse events (SAEs) and no treatment discontinuations due to adverse events (AEs) in patients with IgAN across Cohorts 1 and 2BION-1301 continues to demonstrate rapid and sustained reductions in mechanistic biomarkers, including IgA and Gd-IgA1 levels, in patients with IgAN across Cohorts 1 and 2In Cohort 1, BION-1301 demonstrated mean proteinuria reductions of 30.4% at 12 weeks of treatment, 48.8% at 24 weeks of treatment and 66.9% at 52 weeks of treatment, as well as 6

      11/4/22 10:00:00 AM ET
      $KDNY
      Biotechnology: Pharmaceutical Preparations
      Health Care